{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:12:05Z","timestamp":1790759525957,"version":"4.1.0"},"reference-count":42,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med Report"],"DOI":"10.3892\/mmr.2018.8408","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T12:06:19Z","timestamp":1515499579000},"source":"Crossref","is-referenced-by-count":7,"title":["The effects of interleukin 2 and rAd-p53 as a treatment for glioblastoma"],"prefix":"10.3892","author":[{"given":"Hai\u2011Bo","family":"Qiao","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian\u2011Jie","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben\u2011Jin","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi\u2011Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"key":"key20200713224453_b1-mmr-17-03-4853","first-page":"S1315, 2015","article-title":"Non-model segmentation of brain glioma tissues with the combination of DWI and fMRI signals","volume":"26","author":"Lu","year":"2015","journal-title":"Biomed Mater Eng"},{"key":"key20200713224453_b2-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/mt.2012.210","article-title":"T cells redirected to EphA2 for the immunotherapy of glioblastoma","volume":"21","author":"Chow","year":"2013","journal-title":"Mol Ther"},{"key":"key20200713224453_b3-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00520-015-2930-3","article-title":"Antiepileptic drug treatment in the end-of-life phase of glioma patients: A feasibility study","volume":"24","author":"Koekkoek","year":"2016","journal-title":"Support Care Cancer"},{"key":"key20200713224453_b4-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1134\/S0026893315020028","article-title":"Expressing foreign genes by Newcastle disease virus for cancer therapy","volume":"49","author":"Bai","year":"2015","journal-title":"Mol Biol (Mosk)"},{"key":"key20200713224453_b5-mmr-17-03-4853","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000436998","article-title":"Immunotherapy of Melanoma","volume":"42","author":"Snyder","year":"2015","journal-title":"Prog Tumor Res"},{"key":"key20200713224453_b6-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.4161\/cbt.29686","article-title":"Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy","volume":"15","author":"Bai","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"key20200713224453_b7-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00262-012-1289-2","article-title":"Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer","volume":"61","author":"Shi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713224453_b8-mmr-17-03-4853","first-page":"7728","article-title":"Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy","volume":"8","author":"Chen","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"key20200713224453_b9-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: A systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20200713224453_b10-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.3171\/2015.1.FOCUS14755","article-title":"A practical review of prognostic correlations of molecular biomarkers in glioblastoma","volume":"38","author":"Karsy","year":"2015","journal-title":"Neurosurg Focus"},{"key":"key20200713224453_b11-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar1533","article-title":"p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis","volume":"7","author":"Yamanishi","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"key20200713224453_b12-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/mc.2940080203","article-title":"Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system","volume":"8","author":"Ohgaki","year":"1993","journal-title":"Mol Carcinog"},{"key":"key20200713224453_b13-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ijc.2910520606","article-title":"The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma","volume":"52","author":"Sakai","year":"1992","journal-title":"Int J Cancer"},{"key":"key20200713224453_b14-mmr-17-03-4853","first-page":"4855","article-title":"Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis","volume":"54","author":"Greenblatt","year":"1994","journal-title":"Cancer Res"},{"key":"key20200713224453_b15-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"},{"key":"key20200713224453_b16-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1177\/0300985814560232","article-title":"Mutations in and expression of the tumor suppressor gene p53 in egg-type chickens infected with subgroup J avian leukosis virus","volume":"52","author":"Yue","year":"2015","journal-title":"Vet Pathol"},{"key":"key20200713224453_b17-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"key20200713224453_b18-mmr-17-03-4853","first-page":"3","article-title":"The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy","volume":"37","author":"Hamzehloie","year":"2012","journal-title":"Iran J Med Sci"},{"key":"key20200713224453_b19-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/BF03349723","article-title":"Tumor suppressor genes in human thyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers","volume":"18","author":"Fagin","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"key20200713224453_b20-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJM199310283291807","article-title":"Clinical implications of the p53 tumor-suppressor gene","volume":"329","author":"Harris","year":"1993","journal-title":"N Engl J Med"},{"key":"key20200713224453_b21-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1067\/mtc.2003.176","article-title":"Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study","volume":"125","author":"Casson","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key20200713224453_b22-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/BF00184117","article-title":"Detection of p53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: Possible clinical implications","volume":"12","author":"Kuczyk","year":"1994","journal-title":"World J Urol"},{"key":"key20200713224453_b23-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.3748\/wjg.v17.i38.4289","article-title":"rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy","volume":"17","author":"Chen","year":"2011","journal-title":"World J Gastroenterol"},{"key":"key20200713224453_b24-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.gene.2012.02.007","article-title":"Synergistic anticancer effect of rAd\/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo","volume":"499","author":"Xie","year":"2012","journal-title":"Gene"},{"key":"key20200713224453_b25-mmr-17-03-4853","volume-title":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals","year":"2011","edition":"8th"},{"key":"key20200713224453_b26-mmr-17-03-4853","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4049\/jimmunol.112.1.420","article-title":"Purification of human T and B lymphocytes","volume":"112","author":"Greaves","year":"1974","journal-title":"J Immunol"},{"key":"key20200713224453_b27-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/gt.2009.14","article-title":"Genetically engineered Newcastle disease virus for malignant melanoma therapy","volume":"16","author":"Zamarin","year":"2009","journal-title":"Gene Ther"},{"key":"key20200713224453_b28-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20200713224453_b29-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/PPO.0b013e3182431a73","article-title":"Immunotherapy for the treatment of glioblastoma","volume":"18","author":"Thomas","year":"2012","journal-title":"Cancer J"},{"key":"key20200713224453_b30-mmr-17-03-4853","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1684\/bdc.2011.1352","article-title":"Cellular immunotherapy and glioblastoma: A hopeful treatment?","volume":"98","author":"Larsen","year":"2011","journal-title":"Bull Cancer"},{"key":"key20200713224453_b31-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1158\/0008-5472.CAN-07-0674","article-title":"Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses","volume":"67","author":"Varghese","year":"2007","journal-title":"Cancer Res"},{"key":"key20200713224453_b32-mmr-17-03-4853","first-page":"3649","article-title":"Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy","volume":"58","author":"Husain","year":"1998","journal-title":"Cancer Res"},{"key":"key20200713224453_b33-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nbt0598-449","article-title":"Novel anti-brain tumor cytotoxins specific for cancer cells","volume":"16","author":"Debinski","year":"1998","journal-title":"Nat Biotechnol"},{"key":"key20200713224453_b34-mmr-17-03-4853","first-page":"4018","article-title":"Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2","volume":"59","author":"Bera","year":"1999","journal-title":"Cancer Res"},{"key":"key20200713224453_b35-mmr-17-03-4853","first-page":"5876","article-title":"Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites","volume":"51","author":"Ghetie","year":"1991","journal-title":"Cancer Res"},{"key":"key20200713224453_b36-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1007\/s00005-008-0047-9","article-title":"Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers","volume":"56","author":"Sinkovics","year":"2008","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"key20200713224453_b37-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1089\/hum.1998.9.17-2503","article-title":"Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma","volume":"9","author":"Yoshida","year":"1998","journal-title":"Hum Gene Ther"},{"key":"key20200713224453_b38-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00262-003-0490-8","article-title":"Further development of local IL-2 therapy of cancer: Multiple versus single IL-2 treatment of transplanted murine colon carcinoma","volume":"53","author":"Kusnierczyk","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713224453_b39-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11934-001-0019-7","article-title":"Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer","volume":"2","author":"Pantuck","year":"2001","journal-title":"Curr Urol Rep"},{"key":"key20200713224453_b40-mmr-17-03-4853","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/cmi.2014.40","article-title":"Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: A phase I\/II trial","volume":"12","author":"Baek","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"key20200713224453_b41-mmr-17-03-4853","first-page":"1993","article-title":"IL-2 gene therapy of advanced lung cancer patients","volume":"16","author":"Tan","year":"1996","journal-title":"Anticancer Res"},{"key":"key20200713224453_b42-mmr-17-03-4853","first-page":"S1268","article-title":"Gene therapy with Adv-IL-2 in unresectable digestive cancer: Phase I\u2013II study, intermediate report","volume":"46","author":"Gilly","year":"1999","journal-title":"Hepatogastroenterology"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T14:04:41Z","timestamp":1693404281000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mmr.2018.8408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":42,"URL":"https:\/\/doi.org\/10.3892\/mmr.2018.8408","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,9]]}}}